Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, HER2-positive breast cancer.
HER2-positive Breast Cancer
DRUG: Pyrotinib|DRUG: Trastuzumab
Disease-free Survival, stimated percentage of patients alive and disease-free at 5 years from randomization or censored at date of last follow-up., 5 years
Breast Cancer Specific Survival, Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer specific survival is defined as the time from randomization to death from breast cancer relapse; or censored at date last known alive., 5 years|Overall Survival, Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive., 5 years|Treatment-related adverse events, Incidence and severity of adverse events as assessed by NCI CTCAE V5.0, up to 3 months|Change of LVEF after treatment, The change of LVEF after 3 months treatment compared to the baseline LVEF, up to 3 months
This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors \<8mm, node-negative, HER2-positive breast cancer.